Cocrystal Pharma Selects Lead Compound for Further Development Against Coronaviruses
December 22, 2020 08:30 ET
|
Cocrystal Pharma, Inc.
CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2 BOTHELL, Wash., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cocrystal...
VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results
February 25, 2019 08:00 ET
|
VBI Vaccines, Inc.
Top-line data from Hepatitis B (Sci-B-Vac®) Phase 3 PROTECT trial expected mid-year 2019Encouraging early immunogenicity data from GBM Phase 1/2a supports advancing into Part B of the studyLicense and...